ArticleBMC bioinformatics2011
Non-nucleosidic inhibition of Herpes simplex virus DNA polymerase: mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin A.
Article in BMC bioinformatics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 67 citations in OpenAlex.
- Withaferin A inhibits Chikungunya virus nsP2 protease and shows antiviral activity in the cell culture and mouse model of virus infection.PLoS pathogens · 2024Article
- Withania somnifera extracts induced attenuation of HIV-1: a mechanistic approach to restrict viral infection.Virology journal · 2023Article
- An exhaustive comprehension of the role of herbal medicines in Pre- and Post-COVID manifestations.Journal of ethnopharmacology · 2022Review
- Molecular Modeling Study of NovelMolecules (Basel, Switzerland) · 2022Article
- A Brief Overview of Potential Treatments for Viral Diseases Using Natural Plant Compounds: The Case of SARS-Cov.Molecules (Basel, Switzerland) · 2021Review
- Withaferin A-A Promising Phytochemical Compound with Multiple Results in Dermatological Diseases.Molecules (Basel, Switzerland) · 2021Review
- Medicinal Plants, Phytochemicals, and Herbs to Combat Viral Pathogens Including SARS-CoV-2.Molecules (Basel, Switzerland) · 2021Review
- Antiviral Potential of Selected Medicinal Herbs and Their Isolated Natural Products.BioMed research international · 2021Review
- Review
- The current understanding and potential therapeutic options to combat COVID-19.Life sciences · 2020Review
- Recent Advances in the Stereoselective Total Synthesis of Natural Pyranones Having Long Side Chains.Molecules (Basel, Switzerland) · 2020Review
- Indian Medicinal Plants and Formulations and Their Potential Against COVID-19-Preclinical and Clinical Research.Frontiers in pharmacology · 2020Review
- Screening and druggability analysis of some plant metabolites against SARS-CoV-2: An integrative computational approach.Informatics in medicine unlocked · 2020Article
- Therapeutic Strategies in the Management of COVID-19.Frontiers in molecular biosciences · 2020Review
- Targeting Neurological Manifestations of Coronaviruses by Candidate Phytochemicals: A Mechanistic Approach.Frontiers in pharmacology · 2020Review
- Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease.Expert opinion on therapeutic targets · 2014Review
- FW-04-806 inhibits proliferation and induces apoptosis in human breast cancer cells by binding to N-terminus of Hsp90 and disrupting Hsp90-Cdc37 complex formation.Molecular cancer · 2014Article
- Blocking protein kinase C signaling pathway: mechanistic insights into the anti-leishmanial activity of prospective herbal drugs from Withania somnifera.BMC genomics · 2012Article
- Towards big data science in the decade ahead from ten years of InCoB and the 1st ISCB-Asia Joint Conference.BMC bioinformatics · 2011Article
- Medicinal Plants Used by Traditional Healers in Sangurur, Elgeyo Marakwet County, Kenya.Pharmacognosy researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes Simplex Virus 1 and 2 causes several infections in humans including cold sores and encephalitis. Previous antiviral studies on herpes viruses have focussed on developing nucleoside analogues that can inhibit viral polymerase and terminate the replicating viral DNA. However, these drugs bear an intrinsic non-specificity as they can also inhibit cellular polymerase apart from the viral one. The present study is an attempt to elucidate the action mechanism of naturally occurring withaferin A in inhibiting viral DNA polymerase, thus providing an evidence for its development as a novel anti-herpetic drug.
resultsWithaferin A was found to bind very similarly to that of the previously reported 4-oxo-DHQ inhibitor. Withaferin A was observed binding to the residues Gln 617, Gln 618, Asn 815 and Tyr 818, all of which are crucial to the proper functioning of the polymerase. A comparison of the conformation obtained from docking and the molecular dynamics simulations shows that substantial changes in the binding conformations have occurred. These results indicate that the initial receptor-ligand interaction observed after docking can be limited due to the receptor rigid docking algorithm and that the conformations and interactions observed after simulation runs are more energetically favoured.
conclusionsWe have performed docking and molecular dynamics simulation studies to elucidate the binding mechanism of prospective herbal drug withaferin A onto the structure of DNA polymerase of Herpes simplex virus. Our docking simulations results give high binding affinity of the ligand to the receptor. Long de novo MD simulations for 10 ns performed allowed us to evaluate the dynamic behaviour of the system studied and corroborate the docking results, as well as identify key residues in the enzyme-inhibitor interactions. The present MD simulations support the hypothesis that withaferin A is a potential ligand to target/inhibit DNA polymerase of the Herpes simplex virus. Results of these studies will also guide the design of selective inhibitors of DNA POL with high specificity and potent activity in order to strengthen the therapeutic arsenal available today against the dangerous biological warfare agent represented by Herpes Simplex Virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.